Form 4: Corcept CEO Sells Shares Under Pre-Arranged Trading Plan
Insider Trading Report
Corcept Therapeutics CEO Joseph K. Belanoff sold 615 shares of common stock for approximately $73.69 per share, executed under a pre-existing Rule 10b5-1 trading plan.
Summary
- Joseph K. Belanoff, Chief Executive Officer, Director, and 10% Owner of Corcept Therapeutics Inc. (CORT), reported a sale of common stock.
- The transaction involved the disposition of 615 shares of Common Stock on July 17, 2025.
- The shares were sold at a weighted average price of $73.6873 per share, with actual sale prices ranging from $73.655 to $73.74.
- This sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Belanoff on November 26, 2024.
- Following this transaction, Mr. Belanoff beneficially owns 2,901,370 shares indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale can be seen as negative, the fact that it's a small amount and part of a pre-arranged 10b5-1 plan mitigates any strong negative implications, making it an expected, routine disclosure.
Positives
- The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled sale rather than a reaction to new, non-public information.
Negatives
- An insider sale, even if pre-planned, can sometimes be perceived as a slight negative signal regarding management's view on future stock performance, though the small volume and 10b5-1 plan mitigate this.
Future Outlook
No forward-looking statements or guidance are provided in this document.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in the CEO's direct beneficial ownership, but the vast majority of his holdings remain indirect through a trust. The pre-planned nature of the sale suggests no immediate negative implications for company prospects.
Key Dates
| Date | Description |
|---|---|
| 04/29/2002 | Date of the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust. |
| 11/26/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 07/17/2025 | Date of the reported transaction (sale of common stock). |
| 07/21/2025 | Date the Form 4 was signed by the attorney-in-fact for Joseph K. Belanoff. |
Keywords
Corcept Therapeutics, CORT, Joseph K. Belanoff, Insider Trading, SEC Form 4, Stock Sale, Rule 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.